SEC Tracker
Get the app

MBX Biosciences MBX

MBX Biosciences Biosciences reports net loss of $62.42 million

MBX Biosciences (MBX) filed a 10-Q with the SEC on Nov 9, 2026, 4:08 pm ET. Source: the filing on SEC EDGAR.

Form
10-Q
Filed
Importance
Notable
  1. Net loss: $62.42 million for the three months ended Sep 30, 2026
  2. Diluted EPS: -$1.29 for the three months ended Sep 30, 2026
  3. Cash and equivalents: $161.69 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when MBX Biosciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

No new risk factors or legal mentions.

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange QoQ
Operating income and margin−$66.34M−$40.93M−62%
Net income−$62.42M−$37.1M−68%
Operating cash flow−$34.88M−$22.62M−54%
Cash$161.69M$54.12M+199%

Data on this page was fetched . The filing on SEC.gov is the record.